News | October 14, 2024
Zydus and ICMR initiate a Phase 2 trial of Desidustat in patients with Sickle Cell Disease
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
We now rank 3rd in pharmaceutical production by volume and 14th by value
CSPC will receive an upfront payment of $100 million from AstraZeneca
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Subscribe To Our Newsletter & Stay Updated
